Clinical Trial: Tibsovo Tablets 250 mg General Drug Use-Results Survey (IDH1-mutated acute myeloid leukaemia)(Japan)

Tokyo, June 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058014) titled 'Tibsovo Tablets 250 mg General Drug Use-Results Survey (IDH1-mutated acute myeloid leukaemia)' on June 2

Study Type:

Observational

Study Design:

Primary Sponser:

Institute - NIHON SERVIER CO., LTD.

Condition:

Condition - IDH1-mutated acute myeloid leukaemia Classification by malignancy - Malignancy Genomic information - NO

Objective:

Intervention:

Eligibility:

Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients with IDH1-mutated acute myeloid leukaemia who received this drug for the first time during the study period and agreed to part...